Where does Qianjiang Yongan Phamaceutical Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Qianjiang Yongan Phamaceutical Co., Ltd. ranks #42,521 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Qianjiang Yongan Phamaceutical Co., Ltd. hold?

Qianjiang Yongan Phamaceutical Co., Ltd. holds 6 US utility patents granted between 2018 and 2024, spanning 3 technology areas.

What is Qianjiang Yongan Phamaceutical Co., Ltd.'s Innovation Score?

Qianjiang Yongan Phamaceutical Co., Ltd. has an Innovation Score of 42.9 out of 100 (top 30% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Qianjiang Yongan Phamaceutical Co., Ltd. focus on?

Qianjiang Yongan Phamaceutical Co., Ltd.'s top technology area is C07C (Acyclic OR Carbocyclic Compounds) with 5 patents, ranking #845 of 2,691 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

Is Qianjiang Yongan Phamaceutical Co., Ltd.'s patent grant rate increasing or decreasing?

Qianjiang Yongan Phamaceutical Co., Ltd.'s recent grant velocity is +400% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Qianjiang Yongan Phamaceutical Co., Ltd.'s patents?

Qianjiang Yongan Phamaceutical Co., Ltd.'s patents average 16.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Qianjiang Yongan Phamaceutical Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Qianjiang Yongan Phamaceutical Co., Ltd.

USPTO PatentsView assignee record - 6 granted patents across 3 technology areas, recorded in grant years 2018–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07C (Acyclic OR Carbocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Qianjiang ranks #42,521 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 3 technology areas.

#42,521
of 49,997 US assignees by volume: Top 30%
by Innovation Score (42.9/100): 16.7
avg claims per patent: +400%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R42521 · Foreign Corporation #42,521 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #42,521/49,997
PHOTO-FINISH QGP
CPC-NARROW C07C · 3 areas
INNOV-PAR 42.9/100
CLAIMS-RICH 16.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +400% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: QGP, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Qianjiang’s 42.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (16%) Velocity 20.0 pts (47%) Breadth 6.1 pts (14%) Claim depth 10.0 pts (23%)

Qualcomm Incorporated · highest

85
Qianjiang Yongan… · this assignee

43
3D Lighting… · lowest

7

What this shows Qianjiang's Innovation Score is 42.9/100 (top 30% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Qianjiang?

Each dot is one of Qianjiang’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Qianjiang’s own 16.7 claims/patent is ABOVE the 10.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Qianjiang vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Qianjiang's grants concentrate

Qianjiang Yongan Phamaceutical Co., Ltd. is a focused PatentsView assignee: 3 CPC subclasses with 83.3% of grants classified under C07C (Acyclic OR Carbocyclic Compounds). Peak complete grant year is 2022 (2 grants) versus a trough of 1 in 2018. By volume, Qianjiang sits between QGP, LLC and Qingdao Jiaonan Haier Washing Machine Co., Ltd..

Qianjiang's three-year grant acceleration

Qianjiang Yongan Phamaceutical Co., Ltd. shows 4 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

QGP

6
Qiagen Healthcare…

6
Qiagen Manchester

6
Qiagen Redwood Ci…

6
Qiduo E-commerce…

6
Qierling (Beijing…

6
Qingdao Haier Spe…

6
Qingdao Jiaonan H…

6
Qianjiang Yongan… ◀

6

What this shows Qianjiang holds 6 patents at rank #42,491, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Qianjiang

By rank, the assignees closest to #42,491 in granted patent volume.

Leaders in C07C (Acyclic OR Carbocyclic Compounds)

Other assignees with the most granted patents in Qianjiang's primary technology class.

Qianjiang's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 30% higher than 70% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Qianjiang Yongan Phamaceutical Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	16.7%
2021	1	16.7%
2022	2	33.3%
2023	1	16.7%
2024	1	16.7%

Which technologies does Qianjiang Yongan Phamaceutical Co., Ltd. patent most?

C07C - Acyclic OR Carbocyclic Compounds 5

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 2

B01D - Separation 2

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Qianjiang Yongan Phamaceutical Co., Ltd.'s patent record in context - here's where to go next.

Qianjiang Yongan Phamaceutical Co., Ltd.'s lead technology class is C07C (Acyclic OR Carbocyclic Compounds), 83.3% of its portfolio - see every assignee active in that class. Explore C07C
Ranked #42,521 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Qianjiang Yongan Phamaceutical Co., Ltd. against QGP, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 42.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.